KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Shares Outstanding (Diluted Average) (2020 - 2025)

Royalty Pharma's Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $564.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 4.99% year-over-year to $564.5 million; the TTM value through Dec 2025 reached $564.5 million, down 4.99%, while the annual FY2025 figure was $564.5 million, 4.99% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $564.5 million at Royalty Pharma, up from $559.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $607.3 million in Q1 2023 and bottomed at $414.8 million in Q4 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $600.2 million (2023), against an average of $578.3 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) soared 71.52% in 2021 before it dropped 6.06% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $414.8 million in 2021, then grew by 5.59% to $438.0 million in 2022, then surged by 37.66% to $602.9 million in 2023, then dropped by 1.46% to $594.1 million in 2024, then fell by 4.99% to $564.5 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Shares Outstanding (Diluted Average) are $564.5 million (Q4 2025), $559.6 million (Q3 2025), and $562.3 million (Q2 2025).